Why does Lyrica® (generic name pregabalin) help some FM patients and not others?
The Department of Anesthesiology at the University of Utah, Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).
Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.
According to the July 10 blood biomarkers study announcement:
• Researchers hope to learn more about why Lyrica is effective for some patients and not for others.
• Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are not currently using Lyrica are needed to participate in this IRB-approved trial.
• Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.
• For more information, contact Andrea White (firstname.lastname@example.org)
* As Pfizer’s Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals.